Human medicines European public assessment report (EPAR): Opdualag, relatlimab,nivolumab, Date of authorisation: 15/09/2022, Revision: 8, Status: Authorised

Timetable: Annual renewal application of conditional marketing authorisation

Timetable: Annual reassessment - ATMP

Timetable: Annual reassessment

Timetable: Annual renewal application of conditional marketing authorisation - ATMP

Human medicines European public assessment report (EPAR): Poherdy, pertuzumab, Date of authorisation: 23/04/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Yesintek, ustekinumab, Date of authorisation: 14/02/2025, Revision: 4, Status: Authorised

List of medicinal products under additional monitoring

List of medicinal products under additional monitoring

List of medicines under additional monitoring